Colorectal CancerNCT06712901
Social Media and Cancer Screening Information
A study testing Median Ranked Cancer Screening Messaging, Overall Preferred Cancer Screening Messaging and Black American Preferred Cancer Screening Messaging in people with Colorectal Cancer, run by University of Utah at 1 site in United States.
Trial summary
NORC/AmeriSpeak will recruit participants who meet the study criteria and invite them to complete a 15-minute survey. Participants will be randomly assigned to one of five conditions, with approximately 400 people in each condition, and will respond to various questions after viewing the study messaging. Read more about this study
- Who is it for?
- Ages 45 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- Median Ranked Cancer Screening Messaging, Overall Preferred Cancer Screening Messaging and Black American Preferred Cancer Screening Messaging
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,030 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jan 2025to 21 Jan 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Identify as white/Caucasian or Black/African American.
Who cannot join
- Do not identify as white/Caucasian or Black/African American.
- Previously diagnosed with colorectal cancer
- Non-English speakers
Trial locations and contacts
1 site in 1 country.
About this study
NORC/AmeriSpeak will recruit participants who meet the study criteria and invite them to complete a 15-minute survey. Participants will be randomly assigned to one of five conditions, with approximately 400 people in each condition, and will respond to various questions after viewing the study messaging. Once 2,000 participants complete the survey, the data will be de-identified and provided to the study team for analysis.
Read the detailed description
NORC/AmeriSpeak will put all of the study content into their system. They will send out the opportunity to participate in the study, which should take about 15 minutes, to people in their panel who meet our participation criteria. Participants will be directed to the study information sheet that includes all elements of consent. Participants who agree to participate will start the survey experiment. The survey experiment will randomize participants into one of five conditions: (1) control (no exposure), (2) overall median ranked messages (from the prior study), (3) messages preferred by all participants, (4) messages preferred by Black American participants, and (5) messages preferred by White American participants. Approximately 400 people will complete each condition. After viewing the study stimuli (or no stimuli in the control condition), participants will respond to various outcomes and other variables of interest (see questionnaire draft included). After all 2,000 people have completed the study, the study team will receive a de-identified data file from NORC/AmeriSpeak with all study data and engage in analysis. This study is planned to close the study around that time as the study team completes data analysis and write-up the findings.
- Conditions
- Colorectal Cancer
- Being tested
- Median Ranked Cancer Screening Messaging, Overall Preferred Cancer Screening Messaging, Black American Preferred Cancer Screening Messaging, White American Preferred Cancer Screening Messaging, Control
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Median Ranked Cancer Screening MessagingBehavioural
Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.
Overall Preferred Cancer Screening MessagingBehavioural
Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.
Black American Preferred Cancer Screening MessagingBehavioural
Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.
White American Preferred Cancer Screening MessagingBehavioural
Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.
ControlBehavioural
There will be no message content of cancer screening and sharing intentions in this arm.
| Study group | Role | What they receive |
|---|---|---|
| Control (no exposure) | Placebo comparator | Participants in the Control Arm will not be shown any messages. Receives: Behavioral: Control |
| Median Ranked | Experimental | Participants in the Median Ranked Arm will be shown four Median Ranked messages. Receives: Behavioral: Median Ranked Cancer Screening Messaging |
| Overall Preferred | Experimental | Participants in the Overall Preferred arm will be shown four Overall Preferred messages. Receives: Behavioral: Overall Preferred Cancer Screening Messaging |
| Black American Preferred | Experimental | Participants in the Black American Preferred arm will be shown four Black American Preferred messages. Receives: Behavioral: Black American Preferred Cancer Screening Messaging |
| White American Preferred | Experimental | Participants in the White American Preferred arm will be shown four White American Preferred messages. Receives: Behavioral: White American Preferred Cancer Screening Messaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intentions to Adhere to Colorectal Cancer Screening (CRCS) Recommendations
After reading cancer screening (CRCS) recommendations, this outcome will assess how likely they are to follow on the the screening recommendations.
Response options: Very unlikely (1), unlikely, neither unlikely nor likely, likely, very likely (5)
A higher score indicates a favorable outcome, and a lower score indicates a less favorable outcome.
Measured: 15 minutes
Intentions to Adhere Test Preference Indication
To determine which colorectal cancer screening (CRCS) participants are most likely to choose.
Response options: stool-based tests (e.g., FOBT or FIT); endoscopic/scoping approach (e.g., colonoscopy or sigmoidoscopy); whatever my doctor recommends to me; something other than a stool-based or scoping approach; I would not follow the recommendations.
This outcome will report the count of responses.
Measured: 15 minutes
Secondary outcomes (2)
Likelihood of Sharing Information Via Social Media
This outcome measure will determine how likely participants are to share the messages about colon cancer screening on social media.
Response options: Very unlikely (1), unlikely, neither unlikely nor likely, likely, very likely (5)
A higher score indicates a favorable outcome, and a lower score indicates a less favorable outcome.
Measured: 15 minutes
Information Sharing Behavior
This outcome will report the count of participants will seek more information after the study.
The participants will be asked a question on if they would like more information (Yes/No) and survey vendor will track participants who click a link to an external resource like the American Cancer Society to learn more.
Measured: 15 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2024
- Study start9 Jan 2025
- Primary completion21 Jan 2025
- Study completion21 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 2,030 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), AmeriSpeak - NORC
- Responsible party
- Sponsor
- Investigators
- Andy King, PhD, Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06712901
- Sponsor's protocol ID
- 183491
- Other IDs
- 5R37CA259156-04
- Status last verified
- Mar 2026
- First submitted
- 19 Nov 2024
- Last updated
- 23 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data will be shared/uploaded to an online data repository like OSF.
Publications
King AJ, Liao Y, Chen T, Kanrar R, Chunara R, Margolin D, Nettleton D, Niederdeppe J. Testing the effects of segmented crowdsource-selected messages to improve intentions to follow colorectal cancer screening recommendations: study protocol for a randomized controlled trial. BMC Public Health. 2026 Jan 31;26(1):755. doi: 10.1186/s12889-026-26440-2.
PubMed 41620698
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Social Media and Cancer Screening Information
- ClinicalTrials.gov ID
- NCT06712901
- Acronym / sponsor ID
- 183491
- Conditions
- Colorectal Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,030 participants (actual)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), AmeriSpeak - NORC
- Study start
- 9 Jan 2025 (actual)
- Primary completion
- 21 Jan 2025 (actual)
- Study completion
- 21 Jan 2025 (actual)
- First posted
- 2 Dec 2024 (actual)
- Results
- Posted 20 Mar 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
NORC/AmeriSpeak will recruit participants who meet the study criteria and invite them to complete a 15-minute survey. Participants will be randomly assigned to one of five conditions, with approximately 400 people in each condition, and will respond to various questions after viewing the study messaging. Once 2,000 participants complete the survey, the data will be de-identified and provided to the study team for analysis.
Detailed description
NORC/AmeriSpeak will put all of the study content into their system. They will send out the opportunity to participate in the study, which should take about 15 minutes, to people in their panel who meet our participation criteria. Participants will be directed to the study information sheet that includes all elements of consent. Participants who agree to participate will start the survey experiment. The survey experiment will randomize participants into one of five conditions: (1) control (no exposure), (2) overall median ranked messages (from the prior study), (3) messages preferred by all participants, (4) messages preferred by Black American participants, and (5) messages preferred by White American participants. Approximately 400 people will complete each condition. After viewing the study stimuli (or no stimuli in the control condition), participants will respond to various outcomes and other variables of interest (see questionnaire draft included). After all 2,000 people have completed the study, the study team will receive a de-identified data file from NORC/AmeriSpeak with all study data and engage in analysis. This study is planned to close the study around that time as the study team completes data analysis and write-up the findings.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Control (no exposure) | Placebo comparator | Behavioral: ControlParticipants in the Control Arm will not be shown any messages. |
| Median Ranked | Experimental | Behavioral: Median Ranked Cancer Screening MessagingParticipants in the Median Ranked Arm will be shown four Median Ranked messages. |
| Overall Preferred | Experimental | Behavioral: Overall Preferred Cancer Screening MessagingParticipants in the Overall Preferred arm will be shown four Overall Preferred messages. |
| Black American Preferred | Experimental | Behavioral: Black American Preferred Cancer Screening MessagingParticipants in the Black American Preferred arm will be shown four Black American Preferred messages. |
| White American Preferred | Experimental | Behavioral: White American Preferred Cancer Screening MessagingParticipants in the White American Preferred arm will be shown four White American Preferred messages. |
Who may qualify
- Ages
- 45 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Identify as white/Caucasian or Black/African American.
Key exclusion criteria (3 listed)
- Do not identify as white/Caucasian or Black/African American.
- Previously diagnosed with colorectal cancer
- Non-English speakers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Median Ranked Cancer Screening MessagingStrong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study. | Behavioural | Median Ranked |
| Overall Preferred Cancer Screening MessagingStrong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study. | Behavioural | Overall Preferred |
| Black American Preferred Cancer Screening MessagingStrong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study. | Behavioural | Black American Preferred |
| White American Preferred Cancer Screening MessagingStrong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants. | Behavioural | White American Preferred |
| ControlThere will be no message content of cancer screening and sharing intentions in this arm. | Behavioural | Control (no exposure) |
Primary outcome
Intentions to Adhere to Colorectal Cancer Screening (CRCS) Recommendations
Time frame: 15 minutes
After reading cancer screening (CRCS) recommendations, this outcome will assess how likely they are to follow on the the screening recommendations. Response options: Very unlikely (1), unlikely, neither unlikely nor likely, likely, very likely (5) A higher score indicates a favorable outcome, and a lower score indicates a less favorable outcome.
Intentions to Adhere Test Preference Indication
Time frame: 15 minutes
To determine which colorectal cancer screening (CRCS) participants are most likely to choose. Response options: stool-based tests (e.g., FOBT or FIT); endoscopic/scoping approach (e.g., colonoscopy or sigmoidoscopy); whatever my doctor recommends to me; something other than a stool-based or scoping approach; I would not follow the recommendations. This outcome will report the count of responses.
2 secondary outcomes
Likelihood of Sharing Information Via Social Media
Time frame: 15 minutes
Information Sharing Behavior
Time frame: 15 minutes
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41620698King AJ, Liao Y, Chen T, Kanrar R, Chunara R, Margolin D, Nettleton D, Niederdeppe J. Testing the effects of segmented crowdsource-selected messages to improve intentions to follow colorectal cancer screening recommendations: study protocol for a randomized controlled trial. BMC Public Health. 2026 Jan 31;26(1):755. doi: 10.1186/s12889-026-26440-2.
- Individual participant dataSharing planned: Yes. De-identified data will be shared/uploaded to an online data repository like OSF.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andy King, PhD principal investigator
Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Median Ranked Cancer Screening Messaging, Overall Preferred Cancer Screening Messaging and Black American Preferred Cancer Screening Messaging in people with Colorectal Cancer, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intentions to Adhere to Colorectal Cancer Screening (CRCS) Recommendations (time frame: 15 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06712901, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.